Editorial

AstraZeneca’s Wainua lowered a disease-causing protein but did not reduce heart complications in a major trial

FDA Is Asking the Right AI Question: Who Watches the Model After Approval?

Parkinson’s Gets a Cleaner Dopamine Bet

Europe Made Genomics Mandatory.

Cardiac rehabilitation is now explicitly personalised in Europe. Reimbursement could decide who gets it

The same weight loss produced different metabolic benefits. Diet quality may matter as much as kilograms lost

Endometrial Cancer Prehab Should Not Be a Luxury Experiment

Myasthenia Care Cannot Wait for Crisis

Dermatophilus Changed Pattern.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
